RecruitingPhase 2NCT06824454
Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
Sponsor
Stanford University
Enrollment
90 participants
Start Date
May 15, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Adult kidney transplant patients.
- No known contraindications to Dipyridamole
Exclusion Criteria3
- Contraindications to Dipyridamole.
- Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
- Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDipyridamole 75 MG
Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06824454
Related Trials
Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)
NCT076071971 location
Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
NCT072247631 location
TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation
NCT068297194 locations
The Impact of Phosphate Metabolism on Healthy Aging
NCT037711051 location
Kidney Transplant Improvement Through New Exercise Training to Increase Capacity
NCT074462961 location